{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"5.9","value":"4.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"paramType":"MEDIAN","populationDescription":"All 34 participants were analyzed for this endpoint.","reportingStatus":"POSTED","timeFrame":"From study enrollment to the first date of disease progression or death as a result of any cause, whichever occurs first, up to 3 years","title":"Progression-free Survival Assessed by RECIST","type":"SECONDARY","unitOfMeasure":"months"}